Bayer’s Dermatology Unit Sale Said to Attract Teva and PerrigoBy and
Buyout firms including Nordic, KKR, Bain may also weigh bids
Initial offers for the assets are due in the coming weeks
Bayer AG’s dermatology unit is attracting interest from a number of health-care and private equity firms as the German company seeks to raise cash for its $66 billion acquisition of Monsanto Co., according to people with knowledge of the matter.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.